FORT MYERS, Fla. — NeoGenomics said it has launched RaDaR ST, a circulating tumor DNA assay designed to detect molecular residual disease across multiple solid tumor types, expanding its offerings in precision oncology diagnostics.
RaDaR ST is intended to provide patient-specific molecular insights by identifying trace amounts of tumor DNA in blood, often before disease recurrence is visible through conventional imaging. The company said the test can help clinicians detect residual disease earlier and make more informed treatment decisions throughout the course of care.
“RaDaR ST represents an important advancement in MRD testing, a rapidly growing market that remains largely untapped,” said Tony Zook, CEO of NeoGenomics. “By providing patient-specific molecular insights, the test enables clinicians to detect residual disease and recurrence sooner than conventional imaging, supporting more informed treatment decisions at each stage of care.”
The assay uses tumor-informed panels built from each patient’s tumor profile and combines whole-exome sequencing with advanced bioinformatics. According to the company, the test can track up to 48 tumor-specific variants and offers a high level of sensitivity and specificity, with a reported limit of detection at a 95 percent probability of 11 parts per million.
NeoGenomics said RaDaR ST has been validated through an expanding body of clinical and real-world evidence, including studies in breast cancer and HPV-negative head and neck cancers. The data indicate the assay can support earlier detection of recurrence, identify patients with persistent molecular disease, and enable long-term surveillance in high-risk populations.
The company said the test is approved by Medicare for its initial launch indications, with two additional indications currently under review for reimbursement.
“These development milestones reflect the brisk pace of innovation across our portfolio and our ongoing commitment to investing in technologies that address emerging clinical needs,” Zook said. “With the launch of RaDaR ST, NeoGenomics now offers a comprehensive solid tumor care solution that spans the continuum of cancer care from diagnostic profiling to personalized MRD assessment, helping guide treatment decisions from diagnosis through long-term monitoring.”
